๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer

โœ Scribed by Michael J. Millward; David R. Newell; Kally Yuen; Jane P. Matthews; Kathryn Balmanno; Christopher J. Charlton; Lindsey Gumbrell; Michael J. Lind; Fiona Chapman; Madeleine Proctor; Dorothy Simmonds; Brian M. J. Cantwell; A. Hilary Calvert

Publisher
Springer
Year
1995
Tongue
English
Weight
756 KB
Volume
37
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pharmacokinetic and pharmacodynamic basi
Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate
โœ Hans Christian Blossey; Hans Erik Wander; Johannes Koebberling; Professor Dr. Ge ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 728 KB

Postmenopausal patients with metastatic breast cancer were treated with medroxyprogesterone acetate (MPA) (Clinovir) in dosages between 500 and 1500 mg orally per day. The relation of MPA plasma concentrations and endocrine effects were studied in a longitudinal fashion. MPA exerted suppressive effe

Clinical activity of cisplatin and prolo
Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: A phase II study
โœ Fried, Getta; Stein, Moshe E.; Haim, Nissim ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 2 views

Background. This phase II study evaluates the antitumor activity and tolerance of cisplatin and prolonged oral administration of etoposide in metastatic breast cancer previously exposed to anthracyclines. Procedure. Twenty-seven patients with metastatic breast cancer who developed tumor progression

Phase II trial of carboplatin and etopos
Phase II trial of carboplatin and etoposide in metastatic breast cancer
โœ John Crown; Thomas Hakes; Bonnie Reichman; David Lebwohl; Theresa Gilewski; Anto ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 345 KB ๐Ÿ‘ 2 views

## Background: High-dose chemotherapy with hematopoietic support produces high rates of response in metastatic breast cancer. to facilitate new high-dose regimens there is a need to identify active agents with toxicity limited to hematopoietic suppression. cisplatin/etoposide is a highly active reg